CT-868

Carmot Therapeutics, Inc. · Phase 2 active Small molecule

CT-868 is a selective inhibitor of a molecular target being developed for metabolic or inflammatory disease.

At a glance

Generic name	CT-868
Sponsor	Carmot Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Mechanism of action

CT-868 is an investigational compound in early clinical development by Carmot Therapeutics. Limited public information is available regarding its precise molecular mechanism and target. The drug is currently in Phase 2 trials, indicating it has completed initial safety and dosage studies.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus (PHASE2)
A Study of CT-868 in Type 1 Diabetes Mellitus (PHASE2)
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose (PHASE1)
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results